Culp stock price, CFI

Culp stock chart:



Culp close price: 32.4

Stock price forecast:

UP TO +1.70%
Target: 32.95

Total forecasts: 81
Reached: 33 (40.74%)

Total Win: 32.64 (99.90%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90833440.96%34.231.26%1,569.1015.200.97%49.431.84%
3023730.43%8.171.15%505.4512.952.56%21.122.92%
1415746.67%8.171.76%256.502.701.05%10.872.29%
78562.50%5.692.29%97.25-0.05-0.05%5.642.23%

Showing 1-10 of 475 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-04-2332.432.950000-00-00
2017-04-2232.433.040000-00-00
2017-04-2132.4533.090000-00-00
2017-04-2031.432.422017-04-20
2017-04-1930.8531.982017-04-20
2017-04-1831.1532.352017-04-20
2017-04-1730.9532.12017-04-20
2017-04-1630.9532.142017-04-20
2017-04-1530.9532.172017-04-20
2017-04-1430.9532.212017-04-20

Culp latest news:


  • 04/12/2017 15:28:41

    Sculptor Of Wall Street Bull Says 'Fearless Girl' Horns In On His Work

    Arturo Di Modica is not happy that the Fearless Girl now staring down his Charging Bull has effectively turned it into a villain. He and his lawyer are now asking that the new statue be removed.

  • 02/13/2017 09:31:02

    Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

    Shares of Zeltiq Aesthetics (ZLTQ) got off to a hot start this week, rallying about 13% Monday after it was announced Allergan (AGN) would acquire the company for $2.47 billion, or about $56.50 per share. Allergan (AGN) shares added about 1%, to $248.86. Zeltiq is another company aimed at keeping people looking younger, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Da...

  • 02/13/2017 06:15:01

    Allergan to acquire body contouring company Zeltiq Aesthetics for $2.5 billion

    Allergan said early Monday it will acquire body-contouring company Zeltiq Aesthetics for $2.475 billion, with the deal expected to close in the second half of this year. Zeltiq Aesthetics has a cooling technology that has been approved for fat reduction, which Allergan said was a $4 billion market opportunity worldwide and growing. Allergan announced in December it would acquire Acelity's LifeCell, which produces various products used for breast reconstruction and soft tissue repair, and its aesthetics business -- including Botox, line fillers, implants and eye care -- is expected to drive much of the company's growth in the coming years. Allergan is creating a "world-class aesthetics business," Chief Executive Brent Saunders said. "With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices," he said. Zeltiq Aesthetics shares, which were halted before the announcement, have surged 25.4% over the last three months. Allergan shares have surged 18.7% over the last three months, compared with a 7.0% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Cummins Inc.CMI-1.84% | Curtiss-Wright CorporationCW | Cushing Renaissance Fund (The)SZC | Customers BancorpCUBI | Customers BancorpCUBI^C | Customers BancorpCUBS | Cutwater Select Income FundCSI | CVENTCVT | CVR Energy Inc.CVI | CVR PartnersUAN |